- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Myelofibrosis with moderate to severe anaemia
- Meeting Date: November 2024
- Public Summary Document (PSD) November 2024 PBAC Meeting - (PDF 845KB)
- Public Summary Document (PSD) November 2024 PBAC Meeting - (Word 182KB)
Momelotinib – November 2024
Momelotinib; Tablet 100 mg (as dihydrochloride monohydrate), Tablet 150 mg (as dihydrochloride monohydrate), Tablet 200 mg (as dihydrochloride monohydrate); Omjjara®
Last updated
30 May 2025